InterCure (INCR) Stock Price, News & Analysis

Company Overview

InterCure Ltd. is an Israeli medical cannabis company that operates through its Canndoc subsidiary. The company is involved in the cultivation, production, distribution and sale of medical cannabis products, serving patients through pharmacies, clinics and other authorized channels.

Its product portfolio includes cannabis flower, oils and other medical cannabis formulations. InterCure has developed a vertically integrated business model that spans cultivation and manufacturing as well as wholesale and retail distribution, with operations primarily focused on Israel.

InterCure has also pursued international expansion through partnerships, licensing arrangements and commercial activities in selected overseas markets, subject to local cannabis regulations. The company’s shares trade on the Nasdaq under the symbol INCR and on the Tel Aviv Stock Exchange.

Key Stats

• Today's Range: $5.30 to $5.35
• 50-Day Range: $4.26 to $5.95
• 52-Week Range: $3.40 to $8.45
• Volume: 3,752 shs
• Average Volume: 43,834 shs
• Market Capitalization: $57.93 million
• P/E Ratio: 35.30
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

InterCure Stock Analysis - MarketRank™

InterCure scored higher than 24% of companies evaluated by MarketBeat, and ranked 795th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

InterCure has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

InterCure has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of InterCure is 35.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.67.

Price to Earnings Ratio vs. Sector

The P/E ratio of InterCure is 35.30, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.49.

Price to Book Value per Share Ratio

InterCure has a P/B Ratio of 0.50. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of InterCure has been sold short.

Short Interest Ratio / Days to Cover

InterCure has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InterCure has recently decreased by 26.15%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InterCure does not currently pay a dividend.

Dividend Growth

InterCure does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InterCure insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.24% of the stock of InterCure is held by insiders.

Percentage Held by Institutions

8.34% of the stock of InterCure is held by institutions.

Company Calendar

• Today: 9/20/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INCR
• CIK: 1857030
• Web: www.intercure.co
• Phone: 972774605012
• Fax: N/A
• Employees: 285
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 35.30
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 1.48
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $78.47 million
• Price / Sales: 0.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.53 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 10,940,000
• Free Float: 10,910,000
• Market Cap: $57.93 million
• Optionable: Optionable
• Beta: 1.42